Clinical trials: Percutaneous Coronary Intervention Patients
ST-elevation Myocardial Infarction
Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction
This is a prospective, multi-centre, open label, randomised study of Phase II that enrolls patients hospitalized with a diagnosis of ST-elevation myocardial infarction (STEMI), comparing Evolocumab versus Standard of Care.
- Trial name
- ExOTIC (NCT04303377)
- Testing
- Evolocumab
- Where
- Italy
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Biomarkers, ST Segment Elevation Myocardial Infarction
Biomarkers for Risk Stratification After STEMI
Despite modern reperfusion strategies, myocardial infarction leads to deleterious processes resulting in left ventricular remodelling (LVR) and heart failure (HF). Several biomarkers i.e.
- Conditions
- Biomarkers, ST Segment Elevation Myocardial Infarction, Primary Percutaneous Coronary Intervention, Heart Diseases
- Trial name
- NCT03735719
- Where
- Poland
- Volunteers
- 136 people
- Sponsor
- Medical University of Warsaw
Acute Coronary Syndrome
Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE)
1. Objective : To test the safety of 6 month-duration of dual antiplatelet therapy (DAPT) compared to conventional 12-month-or-longer duration after second-generation drug-eluting stent (DES) implantation in patients with acute…
- Trial name
- SMART-DATE (NCT01701453)
- Testing
- P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
- Where
- South Korea
- Volunteers
- 2,712 people
- Sponsor
- Samsung Medical Center
Coronary Disease
Postprocedural Contrast Mediated FFR Plus Intracoronary Infusion of Nitroglycerin in Multivessel Patients (PROMETEUS TRIAL)
the use of pressure wires is the standar of care to evaluate angiographically intermediate coronary lesions, however, limitations in the management of these type of lesions continue to be a challenge for the interventional…
- Trial name
- NCT06273293
- Testing
- Fractional Flow Reserve
- Where
- 4 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Fundación EPIC
Coronary Artery Disease
Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
Early stent thrombosis has been noted with increased frequency in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) who are treated with bivalirudin and clopidogrel.
- Trial name
- NCT01789814
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Tufts Medical Center
Coronary Artery Disease, Percutaneous Coronary Intervention
Study on the Preferences for PCI Implantation Devices Among Doctors and Patients
The contemporary percutaneous treatment of coronary artery disease typically involves initial lesion preparation with balloon angioplasty, followed by the deployment of a drug-eluting stent (DES) to provide an immediate scaffold…
- Trial name
- REC-DEVICEPREF (NCT07378163)
- Testing
- Questionnaire
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Xijing Hospital
ST Elevation Myocardial Infarction
Risk Characterization of Non-culprit Vessels in Patients Undergoing Primary PCI for ST-elevation MI in Multivessel Disease
Most heart attacks occur because a clot forms in a coronary artery blocking blood flow. Without blood heart muscle dies. Untreated, clots can cause a specific type of heart attack -ST-elevation myocardial infarction (STEMI).
- Trial name
- PICNIC (NCT06506448)
- Testing
- CT Coronary Angiography
- Where
- 3 sites in United Kingdom
- Volunteers
- 320 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Coronary Artery Disease
Ticagrelore Alone Post PCI
After PCI for CCS patients, single center double blind randomization will be done and patients will receive aspirin 80 mg and clopidogrel 75 mg versus 90 mg two times daily of ticagrelor, for 6 months and MACE will be followed in…
- Trial name
- TICALONE (NCT06509893)
- Testing
- aspirin 80 mg and clopidogrel 75 mg daily, Ticagrelor 90 MG
- Where
- 2 sites in Iran
- Volunteers
- 5,400 people
- Sponsor
- Shiraz University of Medical Sciences
Chronic Total Occlusion of Coronary Artery
Japanese CTO PCI Expert Registry
The purpose of this study is to establish a consensus of treatment strategy of percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) through patient registry of PCI for CTO performed by Japanese certified…
- Trial name
- NCT01889459
- Where
- Japan
- Volunteers
- 19,000 people
- Sponsor
- Kurashiki Central Hospital
ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention
Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction
This is a double-blind, multicenter, randomized, placebo-controlled clinical trial. It is planned to enroll patients admitted with anterior ST-segment elevation myocardial infarction (STEMI) within 6h of symptom onset and undergo…
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention, Cardioprotection
- Trial name
- COOPERATION (NCT04912518)
- Testing
- Dexmedetomidine (DEX)
- Where
- 9 sites in China
- Volunteers
- 250 people
- Sponsor
- Harbin Medical University
Acute Coronary Syndrome
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in ACS patients undergoing an Ad Hoc PCI
- Trial name
- NCT01603082
- Testing
- Ticagrelor, Clopidogrel
- Where
- 16 sites in United States
- Volunteers
- 343 people
- Sponsor
- AstraZeneca
Aortic Stenosis, Coronary Artery Disease
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement
Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis.
- Conditions
- Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis
- Trial name
- COMPLETE TAVR (NCT04634240)
- Testing
- Percutaneous Coronary Intervention (PCI)
- Where
- 72 sites in United States, Canada
- Volunteers
- 4,000 people
- Sponsor
- University of British Columbia
Subject Under Anticoagulant
Prospective Real-world Registry Describing Treatment Regimens
This study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.
- Trial name
- PRAETORIAN (NCT03942913)
- Testing
- an observational study
- Where
- France
- Volunteers
- 573 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Coronary Artery Disease, Coronary Restenosis
The SCRIPPS DES REAL WORLD Registry
This study is a prospective, non-randomized, open-label registry of consecutive patients with CAD treated by stent-assisted PCI using at least one CypherTM stent. Up to 1000 pts will be included in the registry.
- Conditions
- Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis
- Trial name
- NCT00714623
- Testing
- Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)
- Where
- United States
- Volunteers
- 859 people
- Sponsor
- Paul S Teirstein, MD
Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
For patients with ACS undergoing PCI, intensive lipid-lowering including PCSK9 monoclonal antibody should be started as soon as possible, that is, lower LDL-C level should be achieved as soon as possible.
- Conditions
- Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome, Lipid Lowering, Vascular Inflammation
- Trial name
- NCT06096909
- Testing
- Tafolecimab, Cholesterol Absorption Inhibitor, Statin
- Where
- 2 sites in China
- Volunteers
- 3,684 people
- Sponsor
- China National Center for Cardiovascular Diseases
Acute Coronary Syndromes
Cocktail Injection Improves Outcomes of FFR Guided PCI
This is a randomized, single blind, controlled study of intracoronary cocktail injection before fractional flow reserve (FFR) measurement when guiding percutaneous coronary intervention (PCI) in patients with acute coronary…
- Trial name
- CocktailII (NCT02592720)
- Testing
- cocktail, FFR, QCA guided group
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Xijing Hospital
H Pylori Infection
Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding"
In the present study, the aim was to report the prevalence of positive H. pylori infection in an unselected population referred for coronary intervention and likely to required DAPT or DPI, also the study assessed impact of H.
- Trial name
- NCT07487142
- Testing
- BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE
- Where
- Egypt
- Volunteers
- 121 people
- Sponsor
- Beni-Suef University
Coronary Artery Disease
Everolimus- Versus Biolimus-Eluting Stents in All-Comers
This study sought to investigate safety and efficacy of biolimus-eluting stents (BES) with biodegradable polymer as compared with everolimus-eluting stents (EES) with durable polymer through 3 years of follow-up.
- Trial name
- EverBio (NCT01472705)
- Where
- Switzerland
- Volunteers
- 814 people
- Sponsor
- University of Freiburg
Individualized and Combined Effects of Smoking and Diabetes on the Antiplatelet Activity in Patients Undergoing Primary Percutaneous Coronary Intervention
Individualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCI
Background:Diabetes and smoking are common factors found to increase platelet reactivity in patients undergoing primary PCI. Objective: Compare the individualized and combined effects of smoking and diabetes on the antiplatelet…
- Trial name
- NCT05911659
- Testing
- Ticagrelor
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mina Wageh Mohareb
Acute Myocardial Infarction, Percutaneous Coronary Intervention
CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction II (COREA-AMI II)
This study is intended to provide contemporary data on the residual cardiovascular risk in all consecutive patients with acute myocardial infarction, especially in patients who survived stably within one-year after percutaneous…
- Conditions
- Acute Myocardial Infarction, Percutaneous Coronary Intervention, Major Adverse Cardiovascular Events, Bleeding
- Trial name
- NCT02806102
- Testing
- Percutaneous coronary intervention, Dual-antiplatelet therapy
- Where
- 2 sites in South Korea
- Volunteers
- 13,000 people
- Sponsor
- Seoul St. Mary's Hospital